Boehringer Bids To Go Beyond Slowing IPF
Promising Phase II Data In Lung Disease With High Mortality
The family-owned German group is the market leader in idiopathic pulmonary fibrosis with Ofev but the big-selling drug has significant side effects and only slows, but does not stop, the progression of the disease. It is hoping that the Phase III-ready compound BI 1015550 will offer a significant improvement.
You may also be interested in...
BMS Trumpets Breakthrough For Phase III-Bound IPF Drug
Bristol Myers Squibb believes LPA1 receptor inhibition is the best approach to meet the urgent need for well tolerated new pulmonary fibrosis treatment options that can improve symptoms and address the underlying cause of disease.
Boehringer To Acquire Trutino Under Aggressive Cancer R&D Strategy
The family-owned German firm plans to purchase all shares of current partner, Trutino, to gain its systematically delivered cytokine portfolio amid a broader push to diversify and improve its oncology offering.
Sandoz Launches First US Pirfenidone At-Risk After Court Triumphs
Sandoz has introduced the first generic version of Roche’s landmark treatment for idiopathic pulmonary fibrosis, Esbriet (pirfenidone), after downing the originator’s attempts to stymie its launch.